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Background: The different characteristics of usual interstitial pneumonia in patients with
primary Sjögren's syndrome (UIP/pSS) compared with idiopathic pulmonary ﬁbrosis (UIP/
IPF) are not fully understood. This study aimed to compare characteristics, prognosis, and
treatment responses in these patients.
Methods: Among 129 consecutive patients who underwent surgical lung biopsy to diagnose
diffuse lung diseases at Kanagawa Cardiovascular and Respiratory Center between 1998
and 2002, we identiﬁed 10 and 19 patients with UIP/pSS and UIP/IPF, respectively. Baseline
characteristics, chest high-resolution computed tomography (HRCT) and pathological
ﬁndings, and the clinical course were compared between the two groups. Responses to
immunosuppressive therapy were analyzed by comparing pulmonary function and clinical
status before and one year after treatment initiation.
Results: More patients in the UIP/pSS group tended to be female and older than those in the
UIP/IPF group (mean age, 68 years vs. 62 years). In addition, they more commonly exhibited
enlarged mediastinal lymph nodes and bronchial wall thickening on HRCT. Pathologically,
in the UIP/pSS group, interstitial inﬂammation, plasma cell inﬁltration, lymphoid follicles
with germinal centers, cysts, bronchiolitis, and pleuritis were signiﬁcantly more promi-
nent, whereas smooth muscle hyperplasia and ﬁbroblastic foci were milder (all Po0.05).
The prognosis was better for UIP/pSS compared with UIP/IPF patients (P¼0.01). In addition,
immunosuppressive therapy provided better disease control for those with UIP/pSS (83%,
5/6) compared UIP/IPF (7%, 1/15).
Conclusion: This study identiﬁed distinct clinical, radiological, and pathological characteristics of
UIP/pSS compared with UIP/IPF. Immunosuppressive treatment could be a therapeutic option
for UIP/pSS.
& 2014 The Japanese Respiratory Society. Published by Elsevier B.V. Open access under 
CC BY-NC-ND license.Society. Published by Elsevier B.V.
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Interstitial lung disease (ILD) is the most frequent form of lung
involvement in primary Sjögren's syndrome (pSS), and it is
classiﬁed into several patterns including non-speciﬁc inter-
stitial pneumonia (NSIP), usual interstitial pneumonia (UIP),
and organizing pneumonia [1]. Of these, NSIP is the most
common, but UIP is not rare [2–4]. The characteristics of UIP in
patients with collagen vascular diseases (CVDs) compared
with idiopathic pulmonary ﬁbrosis (UIP/IPF) have been eval-
uated in a number of studies [5–8], but none has distinguished
between pSS and other CVDs. Most cases are accompanied by
rheumatoid arthritis or scleroderma, and pSS is relatively rare.
Patients with UIP and CVDs often have a better prognosis than
those with UIP/IPF [6–9]. One study has suggested that the poor
prognosis of patients with UIP and rheumatoid arthritis
resembles that of patients with UIP/IPF [10]. These discrepan-
cies emphasize the importance of analyzing each CVD sepa-
rately. To the best of our knowledge, no study to date has
undertaken a direct comparison of UIP in patients with pSS
(UIP/pSS) compared with those with IPF (UIP/IPF), and the
differences between the two groups are not fully understood.
The prognosis of patients with UIP/pSS is generally favorable,
but cases of progressive and/or symptomatic disease requir-
ing intervention have also been reported [2,3,11]. According to
a recent guideline, immunosuppressive treatments including
corticosteroids and immunosuppressants, such as cyclopho-
sphamide, azathioprine, and cyclosporin, are not recom-
mended for patients with UIP/IPF [12]; however, it is unclear
whether this is also applicable for patients with UIP/pSS.
The aim of this retrospective study was to directly com-
pare the clinical, radiological, and pathological ﬁndings of
patients with UIP/pSS and UIP/IPF, and to evaluate their
prognosis and responses to immunosuppressive therapy.Abbreviations: ATS, American Thoracic SocietyBAL, bronchoalv
capacity for carbon monoxideERS, European Respiratory SocietyFVC
CTIIPs, idiopathic interstitial pneumoniasILD, interstitial lung dise
dehydrogenaseNSIP, non-speciﬁc interstitial pneumoniapSS, prima
UIP/IPF, usual interstitial pneumonia/idiopathic pulmonary ﬁbrosisUIP2. Methods
2.1. Study subjects
We retrospectively reviewed the medical records of 129 con-
secutive patients who underwent a surgical lung biopsy for the
diagnosis of diffuse lung diseases at Kanagawa Cardiovascular
and Respiratory Center between December 1998 and May 2002.
At our institution, a surgical lung biopsy is recommended for
all patients with ILDs bar those who have a poor general
condition, severely deteriorated pulmonary function, or typical
UIP/IPF based on clinical and radiological ﬁndings. We
included patients with a long-term follow-up to determine
the accuracy of the prognosis and clinical course. Of the 129
patients, 10 were categorized as UIP/pSS and 19 as UIP/IPF. The
excluded patients were diagnosed with other idiopathic inter-
stitial pneumonias (n¼34), a form of pSS other than UIP/pSS
(n¼18), or other diffuse lung diseases (n¼48). Rheumatologists
diagnosed pSS on the basis of the diagnostic criteria of the
American–European consensus group [13]. The details of the
pSS diagnosis are summarized in Table 1. The diagnosis of
“UIP” was conﬁrmed according to the pathological criteria of
the 2002 American Thoracic Society/European Respiratory
Society consensus classiﬁcation of idiopathic interstitial pneu-
monias (2002 ATS/ERS classiﬁcation of IIPs) [14]. That is, the
hallmarks of the UIP pattern are patchy and paraseptal
distribution of ﬁbrosis, architectural destruction including
honeycombing, and scattered ﬁbroblastic foci. All patients
diagnosed with UIP/pSS were also included in another recent
study of ours [2], and none had identiﬁable causes for their
lung disease other than pSS. The diagnosis of UIP/IPF was also
based on the 2002 ATS/ERS classiﬁcation of IIPs. The patients
with UIP/IPF had never shown any signs or symptoms of CVDs
during their clinical course. None of the patients in our studyeolar lavageCVD, collagen vascular diseaseDLCO, diffusion
, forced vital capacityHRCT, high-resolution
aseIPF, idiopathic pulmonary ﬁbrosisLDH, lactate
ry Sjögren's syndromeUIP, usual interstitial pneumonia
/pSS, usual interstitial pneumonia/primary Sjögren's syndrome
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pressants at the time of the lung biopsy.
This study was approved by the institutional review board of
Kanagawa Cardiovascular and Respiratory Center (Approval
date: September 24, 2013; Approved #: 25-25.). Given the retro-
spective nature of the study, written informed consent of the
patients was not required.
2.2. Clinical analysis
The clinical information extracted from the medical records
included laboratory results, pulmonary function test results,
and analyses of bronchoalveolar lavage (BAL) ﬂuid obtained
before surgical lung biopsy. If patients began immunosup-
pressive therapy during the clinical course, we compared
their clinical status and changes in forced vital capacity (FVC)
and diffusion capacity for carbon monoxide (DLCO) before
(0–3 months) and one year after (9–15 months) treatment
initiation. Categorical variables indicative of the type of
change (worsened, stable, or improved) were deﬁned by
combining signiﬁcant changes in pulmonary function
(changes in FVC Z10% and/or changes in DLCO Z15%) with
acute exacerbation events, lung transplantation, or death
related to respiratory disorders. We deﬁned “worsened” as a
signiﬁcant decrease in pulmonary function or experiencing at
least one of the abovementioned events. We deﬁned
“improved” as a signiﬁcant increase in pulmonary function
and not experiencing any of these events. All other cases
were regarded as “stable.”
Patients who began immunosuppressive therapy at the
time of an acute exacerbation were excluded from the
response analysis because our focus was the chronic phase
treatment. We used the standard deﬁnition of acute exacer-
bation [15]. If another immunosuppressive drug was included
later in the clinical course, the response analysis only applied
to the ﬁrst treatment regimen.
2.3. Radiological analysis
Before surgical lung biopsy, chest high-resolution CT (HRCT)
scans were obtained for each patient during breath holding at
full inspiration; 1.0- or 2.0-mm thick sections were collectedTable 1 – Detailed diagnostic ﬁndings of patients with primary
Case Agea/sex Dry eyes Dry mouth S/R Li
1 58/M   þ þ
2 65/F þ þ þ N
3 66/F þ þ þ N
4 66/M þ þ þ N
5 67/M þ þ ND þ
6 68/F þ þ ND þ
7 69/M þ þ þ þ
8 71/F þ þ þ þ
9 72/F þ þ þ N
10 74/F þ þ þ N
þ: positive;  : negative; ND: not done; NA: not available; S/R: Schirme
SS-B/La antibody; ANA: anti-nuclear antibody; and RF: rheumatoid facto
a At the time of surgical lung biopsy.throughout the lungs. All images were randomized and
independently reviewed by two experienced radiologists
(T.I. and N.Y.) blinded to clinical and pathological information.
The HRCT scans were analyzed for the presence/absence
of the following characteristics: honeycombing, cysts (no
honeycombing and no emphysema), bronchial wall thicken-
ing, pulmonary artery dilatation, enlarged mediastinal lymph
nodes, and pleural thickening. Semi-quantitative scores were
also provided for the extent of reticular abnormality (reticula-
tion and honeycombing), ground glass attenuation, consoli-
dation, micronodules, and emphysema. The scores were
evaluated at the level of the aortic arch, carina tracheae,
right pulmonary vein, and the top of the right diaphragm in
each lung: 0 (0% of lung parenchyma), 1 (o10%), 2 (10–25%),
and 3 (425%). This analytical approach was described pre-
viously [2,11,16–19].
Subsequently, each scan was classiﬁed as “UIP/IPF pat-
tern,” “possible UIP/IPF pattern,” or “inconsistent with UIP/IPF
pattern” based on the 2011 guideline for the diagnosis and
treatment of UIP/IPF [12]. Disagreements between the two
radiologists after the ﬁrst assessment were resolved by
discussion.
2.4. Pathological analysis
Histological sections of lung biopsy specimens from all
patients were stained with hematoxylin–eosin and elastic
van Gieson. All slides were randomized and independently
reviewed by two experienced lung pathologists (T.T. and K.O.)
who had no access to the clinical and radiological ﬁndings.
The following pathological features were semi-
quantitatively graded as 0 (absent), 1 (mild), 2 (moderate), or
3 (severe): interstitial inﬂammation, plasma cell inﬁltration,
interstitial ﬁbrosis, smooth muscle hyperplasia, lymphoid
follicles with germinal centers, organizing pneumonia (intra-
alveolar polypoid organization), ﬁbroblastic foci, microscopic
honeycombing, emphysema, cysts, cellular bronchiolitis,
bronchiolar ﬁbrosis, vascular medial thickening, perivascular
collagen deposition, and pleuritis. The pathological assess-
ments were performed as previously described [2,6,7,20].
Subsequently, all slides were classiﬁed as “UIP/IPF pattern,”
“probable UIP/IPF pattern,” “possible UIP/IPF pattern,” or “notSjögren's syndrome and usual interstitial pneumonia.
p biopsy Scintigraphy Ro La ANA RF
þ þ  þ 
D ND þ þ þ 
D ND þ þ  
D þ þ NA þ þ
ND þ  þ 
ND þ þ þ 
þ   þ 
ND þ  þ þ
D þ þ  þ þ
D þ þ  þ þ
r's test and/or Rose Bengal test; Ro: anti SS-A/Ro antibody; La: anti
r.
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guideline [12]. Any disagreements between the two pathologists
were discussed until a consensus was reached.
2.5. Statistical analysis
All statistical analyses were performed using SPSS software
version 13.0 (SPSS, Inc., Chicago, IL, USA). Group comparisons
were analyzed by Student's t-test, Mann–Whitney's U-test, or
Fisher's exact test, as appropriate. Survival time was calcu-
lated as the number of months from the date of the surgical
lung biopsy until the date of death or censoring. Patients were
censored if they were lost to follow-up or were alive on July 3,
2012. The Kaplan–Meier method was used to generate survi-
val curves. The log-rank test and Cox's proportional hazards
model were used to compare the prognosis of each group.
The statistical signiﬁcance was set at Po0.05.3. Results
3.1. Patient characteristics and clinical ﬁndings
The baseline clinical characteristics of all patients are listed
in Table 2. Patients in the UIP/pSS group tended to be older
than those in the UIP/IPF group (mean age, 68 years vs. 62
years). The female/male ratio in the UIP/pSS group was also
higher than that in the UIP/IPF group, but was lower than hasTable 2 – Comparison of clinical characteristics, laboratory resu
lavage ﬂuid analyses between patients with primary Sjögren's
pulmonary ﬁbrosis.
Variables UIP/pSS
Age, yearsa 6875 (n¼10
Sex, Male/Female 4/6
Smoking, Never/Current and Former 5/5
BMI, kg/m2 23.373.3 (n¼
Anti-nuclear antibody, Positive/Negative 9/1
Anti-SS–A/Ro antibody, Positive/Negative 9/1
LDH, IU/L 198723 (n¼
KL-6, U/mL (reference range o500) 10667526 (n
IgG, mg/mL 20847623 (n
PaO2, Torr (room air) 75.578.0 (n¼
PaCO2, Torr (room air) 40.873.9 (n¼
Pulmonary function
FVC % pred, % 97.4724.4 (n
FEV1 % pred, % 109.1726.9 (
DLCO % pred, % 88.0723.7 (n
RV/TLC, % 35.976.9 (n¼
Bronchoalveolar lavage ﬂuid
Total cells, /μl 2937313 (n¼
Lymphocytes, % 16.0712.1 (n
CD4/8 ratio 1.170.8 (n¼
Data are presented as number of patients or mean7standard deviation.
IPF using Fisher's exact test or Student's t-test, as appropriate. UIP/p
idiopathic pulmonary ﬁbrosis; BMI: body mass index; LDH: lactate dehydr
arterial oxygen pressure; PaCO2: arterial carbon dioxide pressure; FVC: f
DLCO: diffusion capacity for carbon monoxide; RV: residual volume; TL
height).
a At the time of surgical lung biopsy.been reported in previous reports on pSS [21]. Positivity for
anti-nuclear antibody and anti-SS–A/Ro antibody was signiﬁ-
cantly more frequent, and serum lactate dehydrogenase
(LDH) levels tended to be lower, in the UIP/pSS group
compared with the UIP/IPF group.
The results from the pulmonary function tests and BAL
ﬂuid analyses are also summarized in Table 2. The median
interval between the date of the lung biopsy and the
pulmonary function test or BAL was 35 days (range, 4–200
days) and 37 days (range, 10–213 days), respectively. Pulmon-
ary function was better in the UIP/pSS group, particularly in
terms of FVC and forced expiratory volume in one second.
The ratio of BAL ﬂuid lymphocytes was not signiﬁcantly
different between the two groups, although the CD4/8 ratio
tended to be lower in the UIP/pSS group.3.2. Radiological and pathological ﬁndings
The HRCT ﬁndings are summarized in Table 3. The median
interval between the date of the lung biopsy and HRCT was 12
days (range, 1–148 days). Bronchial wall thickening and
enlarged mediastinal lymph nodes were signiﬁcantly more
common, and the frequencies of cysts and pleural thickening
tended to be higher, in the UIP/pSS group compared with the
UIP/IPF group. None of the patients in the entire cohort
exhibited pleural effusion. The extent of ground glass
attenuation tended to be greater in the UIP/pSS group.lts, pulmonary function test ﬁndings, and bronchoalveolar
syndrome and usual interstitial pneumonia or idiopathic
IPF P-value
) 6277 (n¼19) 0.05
14/5 0.11
5/14 0.24
10) 24.973.2 (n¼15) 0.24
7/12 0.01
1/16 o0.01
9) 224740 (n¼19) 0.08
¼7) 13387573 (n¼18) 0.29
¼10) 17767330 (n¼10) 0.18
10) 75.479.2 (n¼19) 0.99
10) 42.074.6 (n¼19) 0.47
¼10) 81.7718.6 (n¼19) 0.06
n¼10) 88.4719.3 (n¼19) 0.02
¼9) 81.0729.0 (n¼19) 0.54
9) 32.977.2 (n¼19) 0.31
7) 3387144 (n¼17) 0.63
¼8) 11.678.2 (n¼19) 0.28
8) 3.473.5 (n¼11) 0.08
All P-values were evaluated by comparing patients with UIP/pSS and
SS: usual interstitial pneumonia/primary Sjögren's syndrome; IPF:
ogenase; KL-6: Krebs von den lungen-6; IgG: immunoglobulin G; PaO2:
orced vital capacity; FEV1: forced expiratory volume in one second;
C: total lung capacity; and pred: predicted (based on age, sex, and
r e s p i r a t o r y i n v e s t i g a t i o n 5 2 ( 2 0 1 4 ) 2 2 7 – 2 3 5 231The predominant patterns in both groups were the “UIP/IPF
pattern” and “possible UIP/IPF pattern”.
The pathological scores are summarized in Table 4. Multi-
ple lung specimens were collected from most (22/29) patients.
None of the slides were suggestive of diffuse alveolar damage.
Patchy and paraseptal distribution of ﬁbrosis was common in
both groups, whereas partial NSIP-like lesions with alveolitis
and small airway disease were often coexistent in the UIP/pSS
group. A variety of signiﬁcant differences were noted between
the two groups. Interstitial inﬂammation, plasma cell inﬁltra-
tion, lymphoid follicles with germinal centers, cysts, cellular
bronchiolitis, and pleuritis were all signiﬁcantly more promi-
nent in the UIP/pSS group. Follicular bronchiolitis was onlyTable 3 – Comparison of HRCT ﬁndings between the patients w
syndrome and idiopathic pulmonary ﬁbrosis.
HRCT ﬁndings UIP/
Honeycombing, Yes/No 6/4
Cyst, Yes/No 8/2
Bronchial wall thickening, Yes/No 7/3
Pulmonary artery dilatation, Yes/No 1/9
Enlarged mediastinal lymph nodes, Yes/No 8/2
Pleural thickening, Yes/No 2/8
Reticular abnormality, Grade 0/1/2/3 0/5/4
Ground glass attenuation, Grade 0/1/2/3 1/7/1
Consolidation, Grade 0/1/2/3 10/0
Micronodules, Grade 0/1/2/3 4/3/2
Emphysema, Grade 0/1/2/3 4/6/0
Patterna, Inconsistent/Possible/IPF 2b/3/
Data are presented as number of patients. All P-values were evaluated b
Whitney's U-test or Fisher's exact test, as appropriate. The higher grade m
resolution CT; UIP/pSS: usual interstitial pneumonia in primary Sjögren'
a HRCT patterns in accordance with the 2011 guideline of the diagnosis
b Because of extensive ground glass attenuation with prominent micron
c Because of peribronchovascular distribution.
Table 4 – Comparison of pathological features between the pati
syndrome and idiopathic pulmonary ﬁbrosis.
Pathological features, Grade 0/1/2/3 UIP/pSS
Interstitial inﬂammation 0/4/6/0
Plasma cell inﬁltration 0/2/6/2
Interstitial ﬁbrosis 0/3/5/2
Smooth muscle hyperplasia 2/6/2/0
Lymphoid follicle with germinal center 0/6/2/2
Organizing pneumonia 0/10/0/0
Fibroblastic foci 0/5/5/0
Microscopic honeycombing 2/4/3/1
Emphysema 2/4/4/0
Cyst 2/4/1/3
Cellular bronchiolitis 0/5/5/0
Bronchiolar ﬁbrosis 4/5/1/0
Vascular medial thickening 1/3/5/1
Perivascular collagen deposition 6/4/0/0
Pleuritis 2/6/2/0
Patterna, Not/Possible/Probable/IPF 3b/0/0/7
Data are presented as number of patients. All P-values were evaluated
Whitney's U-test. The higher grade means more severe change in patholo
pneumonia in primary Sjögren's syndrome; and IPF: idiopathic pulmona
a Pathological patterns in accordance with the 2011 guideline of the diag
b Because of marked interstitial inﬂammatory cell inﬁltration (n¼2) andfound in the UIP/pSS group (5/10). In contrast, smooth muscle
hyperplasia and ﬁbroblastic foci were signiﬁcantly more severe
in the UIP/IPF group. According to the pathological criteria in
the UIP/IPF guideline, 7/10 patients with UIP/pSS were diag-
nosed with a “UIP/IPF pattern.” Typical HRCT and pathological
images of a patient with UIP/pSS are shown in Fig. 1.3.3. Clinical course and treatment response
The median follow-up period after surgical lung biopsy was
125 months (range, 4–157 months) for the UIP/pSS group and
42 months (range, 12–152 months) for the UIP/IPF group.ith usual interstitial pneumonia in primary Sjögren's
pSS IPF P-value
6/13 0.24
9/10 0.13
3/16 0.01
1/18 1.00
1/18 o0.01
0/19 0.11
/1 0/14/5/0 0.17
/1 4/15/0/0 0.12
/0/0 19/0/0/0 1.00
/1 10/8/1/0 0.25
/0 9/10/0/0 0.71
5 1c/12/6 –
y comparing between the patients with UIP/pSS and IPF using Man–
eans the larger extent on HRCT (see Section 2 for detail). HRCT: high-
s syndrome; and IPF: idiopathic pulmonary ﬁbrosis.
and treatment of IPF [12].
odules or peribronchovascular distribution.
ents with usual interstitial pneumonia in primary Sjögren's
IPF P-value
0/15/4/0 0.04
1/14/3/1 o0.01
0/3/6/10 0.11
0/4/7/8 o0.01
12/6/1/0 o0.01
6/13/0/0 0.18
1/3/6/9 0.03
3/11/4/1 0.70
6/10/1/2 0.30
12/3/4/0 0.03
11/8/0/0 o0.01
9/8/1/1 0.80
3/9/5/2 0.38
9/9/1/0 0.54
18/1/0/0 o0.01
0/0/4/15 –
by comparing between the UIP/pSS and IPF patients using Mann–
gical assessment (see Section 2 for detail). UIP/pSS: usual interstitial
ry ﬁbrosis.
nosis and treatment of IPF [12].
predominant airway-centered changes (n¼1).
Fig. 1 – HRCT and pathological images of a 68-year-old woman with primary Sjögren's syndrome and usual interstitial
pneumonia. (a) and (b) HRCT scans showing subpleural reticulation (i.e., honeycombing, cysts, and traction bronchiectasis).
The shadow is partially located along the bronchovascular bundles. (c) The distribution of ﬁbrosis is predominantly patchy
and paraseptal (hematoxylin–eosin, 10). (d) Tissue combined NSIP-like lesion with mild-to-moderate alveolar inﬂammation
and ﬁbrosis on the same slide. Fibroblastic foci are shown by the straight arrows (hematoxylin–eosin, 40).
HRCT: high-resolution CT; NSIP: non-speciﬁc interstitial pneumonia.
Fig. 2 – Kaplan–Meier survival curves for patients
with primary Sjögren's syndrome and usual
interstitial pneumonia compared with those with
idiopathic pulmonary ﬁbrosis. Survival curves of
patients with UIP/pSS (n¼10) and IPF (n¼19). Perpendicular
bars indicate censored cases. UIP/pSS: primary Sjögren's
syndrome and usual interstitial pneumonia; IPF: idiopathic
pulmonary ﬁbrosis.
r e s p i r a t o r y i n v e s t i g a t i o n 5 2 ( 2 0 1 4 ) 2 2 7 – 2 3 5232A total of 4 and 16 patients with UIP/pSS and UIP/IPF,
respectively, died between follow-up visits, and none of the
patients had to undergo lung transplantation. The Kaplan–
Meier curves generated for the two groups (Fig. 2) revealed a
signiﬁcant prognostic difference by the log-rank test (P¼0.01).
The prognosis of patients in the UIP/IPF group was signiﬁ-
cantly worse even when the baseline was adjusted by age and
FVC% predicted (hazard ratio on risk of death: 3.63 for the
UIP/pSS group, 95% conﬁdence interval 1.15–11.47, P¼0.03).
The detailed clinical courses are summarized in Table 5.
Acute exacerbation and pneumothorax were relatively fre-
quent complications in the UIP/IPF group. There was no
signiﬁcant difference in the frequencies of respiratory tract
infections or lung cancer between the two groups. Although
causes of death were diverse in both groups, none of the
patients died of lung cancer.
Immunosuppressive therapy was initiated during the
chronic phase in 6/10 patients with UIP/pSS and in 15/19
patients with UIP/IPF diagnosed with progressive and/or
symptomatic disease by both clinicians. The ﬁrst treatment
regimens and the responses are also summarized in Table 5.
Oral prednisolone 0.5 mg/kg/day alone or in combination with
cyclosporine (target serum trough level at 100–150 ng/mL)
was frequently selected. The prednisolone dose was tapered
based on the clinician's assessment and was generally
r e s p i r a t o r y i n v e s t i g a t i o n 5 2 ( 2 0 1 4 ) 2 2 7 – 2 3 5 233maintained at a dose of 5–10 mg/day. None of the patients
in either group experienced any signiﬁcant improvement
following immunosuppression, but “stable” disease was
obtained in 5/6 patients (83%) in the UIP/pSS group compared
with 1/15 patients (7%) in the UIP/IPF group (Po0.01). The
impacts of treatment on FVC and DLCO are shown in Fig. 3. In
patients with UIP/IPF, these parameters of pulmonary func-
tion commonly deteriorated within one year after treatment
initiation. In the UIP/pSS group, they were almost stable
during the ﬁrst year but declined 4–5 years later.4. Discussion
This is the ﬁrst study to report on a direct comparison of
pathologically-proven UIP/pSS and UIP/IPF. Various differ-
ences in baseline clinical, radiologic, and pathologic ﬁndings
were found between the two groups. The prognosis was
signiﬁcantly better for patients with UIP/pSS, and disease
progression was favorably controlled by immunosuppressive
therapy within a one-year period.
Several key ﬁndings and parameters distinguished UIP/
pSS from UIP/IPF. Female sex, autoantibody positivity, lower
serum LDH, and a lower CD4/8 ratio in BAL ﬂuid generally
favored a diagnosis of UIP/pSS. Analyses of HRCT scans also
identiﬁed bronchial wall thickening and enlarged mediastinal
lymph nodes as key determinants of UIP/pSS, and patients
with UIP/pSS had more prominent inﬂammatory cell inﬁltra-
tion, lymphoid follicles with germinal centers, and more
extensive pleuritis upon pathological analysis compared with
patients with UIP/IPF. These are reportedly common patho-
logical features of CVDs and lung-dominant CVDs in previousTable 5 – Comparison of the clinical course and treatment betw
Sjögren's syndrome and idiopathic pulmonary ﬁbrosis.
UIP/pS
Acute exacerbation, Yes/No 1/9
Respiratory tract infection, Yes/No 2/8
Lung cancer, Yes/No 2/8
Pneumothorax, Yes/No 0/10
Long-term oxygen therapy, Yes/No 4/6
Status, Alive/Dead (/Drop-out) 5/4 (/1
Causes of death
Chronic respiratory failure 2
Acute exacerbation 1
Respiratory tract infection 1
Lung cancer 0
Right heart failure 0
Immunosuppressive treatmenta, Yes/No 6/4
PSL 3
PSLþCyclosporine 2
PSLþCyclophosphamide 0
Cyclosporine 1
Treatment response in one-year period
Worsened/Stable (/Improved) 1/5 (/0
Data are presented as number of patients. All P-values were evaluated by
exact test. UIP/pSS: usual interstitial pneumonia in primary Sjögren's sy
a Cases who were initiated with immunosuppressive treatment at the tistudies [6,22]. In contrast, cyst formation and small airway
diseases were thought to be distinct characteristics of UIP/
pSS. Notably, most of our patients with UIP/pSS were inap-
propriately diagnosed with a “UIP/IPF pattern” based on the
radiological and/or pathological criteria in the recent IPF
guideline [12]. Therefore, detailed analyses of ﬁndings and
multidisciplinary discussion are essential for diagnosing and
distinguishing UIPs with different etiologies.
The ﬁrst case report of UIP/pSS was published in 1995 [23],
and the reported frequency of UIP in patients with pSS has
varied. Ito et al. investigated 33 patients with pSS with
pulmonary involvement, and reported that none of their
patients had UIP, although they did mention the possibility
of an overestimation of the frequency of NSIP [24]. On the
other hand, 20–67% of patients with ILD and pSS have been
found to have UIP/pSS in other reports [2–4]. This variation in
the prevalence of UIP/pSS might be explained by the back-
ground population and case selection, or it may indicate a
difﬁculty with the diagnosis of UIP, because variations in
pathological ﬁndings, especially the coexistence of UIP and
NSIP patterns, is frequently observed in patients with pSS.
Prognosis and response to immunosuppressive therapy
were signiﬁcantly better in patients with UIP/pSS. The com-
plication rate of acute exacerbation, which is often life-
threatening for patients with ILD [15,25], also tended to be
lower in these patients compared with those with UIP/IPF.
The rate of respiratory tract infection was not signiﬁcantly
different between groups, despite the fact that a previous
study reported a high infection rate in patients with pSS due
to airway diseases [26]. It is unclear whether the distinct
radiological features of UIP/pSS can explain the better clinical
outcome. However, an explanation may be found in theeen patients with usual interstitial pneumonia in primary
S IPF P-value
8/11 0.11
8/11 0.41
3/16 1.00
7/12 0.06
15/4 0.05
) 2/16 (/1) 0.02
4 –
6 –
4 –
0 –
2 –
15/4 –
6 –
8 –
1 –
0 –
) 14/1 (/0) o0.01
comparing between the patients with UIP/pSS and IPF using Fisher's
ndrome; IPF: idiopathic pulmonary ﬁbrosis; and PSL: predonisolone.
me of acute exacerbation were included in “No.”
Fig. 3 – Impact of immunosuppressive therapy on parameters of pulmonary function in patients with primary Sjögren's
syndrome and usual interstitial pneumonia compared with those with idiopathic pulmonary ﬁbrosis. Impact of
immunosuppressive therapy on FVC (a) and DLCO (b). Baseline parameters before treatment are compared with those
measured 1 year and 4–5 years after treatment initiation. Patients without available data at 1 year were excluded. FVC: forced
vital capacity; DLCO: diffusion capacity for carbon monoxide; UIP/pSS: primary Sjögren's syndrome and usual interstitial
pneumonia; IPF: idiopathic pulmonary ﬁbrosis.
r e s p i r a t o r y i n v e s t i g a t i o n 5 2 ( 2 0 1 4 ) 2 2 7 – 2 3 5234pathological ﬁndings. Patients with UIP/pSS had more pro-
minent inﬂammation and milder ﬁbrosis than those with
UIP/IPF, which implies that those with UIP/pSS had more
marginal lesions that were better able to respond to immu-
nosuppressive therapy. In addition, the severity of ﬁbroblastic
foci, which is a predictor of poor prognosis [2,6,7,27], was
signiﬁcantly lower in the lungs of patients with UIP/pSS. On
the other hand, most of our patients with UIP/IPF were
treated with immunosuppressive drugs, which has not been
recommended in the recent guideline [12,28]. This could have
been partly responsible for the poor prognosis of patients in
the UIP/IPF group.
Whether UIP/pSS should be treated by immunosuppres-
sive drugs or not is unclear, whereas most clinicians will
conﬁdently initiate treatment if the diagnosis is NSIP or
organizing pneumonia. Our ﬁndings appear to support the
use of immunosuppressive drugs for the treatment of UIP/
pSS, although over the long term disease progression became
uncontrollable in most cases. In a previous report, azathiopr-
ine alone or in combination with corticosteroids was sug-
gested to improve FVC in patients with pSS and pulmonary
involvement [29]. However, it is unclear how many respon-
ders had UIP because not all patients underwent a surgical
lung biopsy. Perambil et al. reported disease progression in all
three patients with UIP/pSS in their cohort even during
immunosuppression [3]. This apparent discrepancy with our
results may be explained by the difference in the period of
response analysis, which was not deﬁned in their report,
and/or because their patients with UIP/pSS had more severe
disease than those in our study (mean baseline DLCO %
predicted 44% vs. 88%). Their patients may already have hadirreversible progressed ﬁbrosis. In contrast, we reported that
4/10 patients with UIP/pSS had stable or slightly worsened
disease and did not require treatment. It is unclear whether
all patients with UIP/pSS require immunosuppression. We
propose that the initiation of immunosuppressive therapy
should be considered only when the disease is progressive or
symptomatic.
There are several limitations to this study. First, this was a
retrospective study performed at a single center. Since this
study focused on patients who underwent a surgical lung
biopsy at our institution, there is a possibility of selection
bias. Second, the small sample size makes it difﬁcult to draw
any ﬁrm conclusions. Third, our treatment response analysis
was performed using non-uniﬁed treatment regimens with
non-deﬁnite criteria for treatment initiation. The response to
each individual regimen was not evaluated because of the
small number of subjects. Prospective, multicenter, large-
scale, and long-term randomized controlled studies are
required to conﬁrm our ﬁndings, although this may be a
challenge given the rarity of the disease. New drug candi-
dates targeting lymphocytes, molecules, and receptors have
recently been identiﬁed based on the pathogenesis of pSS
[30], and future studies should optimize the treatment regi-
men for ILD in patients with pSS in conjunction with these
new drugs.5. Conclusion
This detailed retrospective study demonstrates that UIP/pSS
is characterized by clinical, radiological, and pathological
r e s p i r a t o r y i n v e s t i g a t i o n 5 2 ( 2 0 1 4 ) 2 2 7 – 2 3 5 235characteristics distinct from those of UIP/IPF, which may lead
to the establishment of a speciﬁc diagnostic proﬁle. Immu-
nosuppressive therapy could be suitable for patients with
pSS, even those with a UIP pattern of ILD.Conﬂict of interest
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